Organic Active Ingredients TRIZ Cases

Merging VEGF-R and CXCR4 antagonists overcomes treatment resistance by suppressing HIF-2α expression and reducing neoangiogenesis.

Maqui berry extract inhibits Candida filamentation, reducing toxicity and resistance risks from traditional antifungals.

Nutritional composition with Fut2-dependent oligosaccharides and Lacto-N-neotetraose promotes infant brain catch-up growth.

Optimized crystallization conditions yield stable ACP-2 polymorphs with low hygroscopicity, resolving preparation complexity trade-offs.

Kv3 channel modulators treat neuropathic pain by targeting neuronal hyperexcitability, avoiding opioid dependence risks.

Beta-cyclodextrins form inclusion complexes with riluzole to enable safe intrathecal administration without oral adverse events.

Two-step wet chemistry deposits DCPD precursors then transforms them into biomimetic apatite for tunable surface properties.

An iontophoresis device uses pulsed and direct current to drive vitamin C across the skin, resolving solubility and stability trade-offs in cosmetic delivery.

Novel small molecules disrupt beta-catenin and BCL9 protein binding to block Wnt signaling pathways in cancer treatment.

Sublingual spray formulation delivers sildenafil through buccal epithelium using ethanol and caprylic acid permeation enhancers.

A method isolating polymethoxyflavones from citrus peel oil using thin-film vacuum distillation and active carbon refining.

Silver compounds catalyze cyclization to produce 1,2,4-triazole derivatives, eliminating toxic mercury and reducing reaction time from days to hours.

Selective mGlu5 antagonists overcome ineffective mGlu1 treatments to inhibit the micturition reflex in lower urinary tract disorders.

A levonorgestrel butanoate suspension uses controlled particle sizing and wetting agents to deliver stable, long-lasting contraceptive efficacy.

Sequencing cell-free DNA for BCAR4 gene fusions stratifies HER2-negative patients, improving treatment efficacy and reducing hormone resistance.

A gastroretentive and delayed release levodopa formulation maintains undetectable plasma levels for two hours post-administration.

Peptide-drug conjugates react with multi-arm PEG to create cross-linked hydrogels that deliver targeted therapy while preventing systemic distribution.

Optimizing the ratio of capsaicinoids to non-capsaicinoids like flavonoids enhances biological efficacy while maintaining feasible extraction processes.

Chiral pool synthesis eliminates resolution steps to boost beraprost yield while maintaining high chiral purity.

GluN2D and mGluR2 inhibitors resolve slow onset of action by enhancing synaptic plasticity without anaesthetic side effects.

Vaporized endothermic gas cools and sanitizes skin to eliminate injection pain and infection risk.

Pyrazolyl derivatives inhibit MALT-1 to dampen NF-kB signaling, addressing inadequate efficacy of current small molecule inhibitors.

Topoisomerase I inhibitor conjugated to a macromolecule via beta elimination linkage enables controlled drug release.

Combining forehead-applied progesterone with punctal plugs addresses ineffective transdermal delivery for chronic ocular graft-versus-host disease.

Substituted pyrido[2,3-d]pyrimidinones resolve selectivity trade-offs by targeting Cdk4 and Cdk6 to suppress tumor growth while protecting normal cells.

Cycloalkenyl aryl derivatives inhibit cholesterol ester transfer protein activity to modulate lipid profiles.

A 6-carbamate substituted heteroaryl compound blocks KRAS G12C and SOS1 binding to inhibit tumor growth.

Wet granulation converts crystalline ticagrelor into an amorphous solid dispersion using hydrophilic polymers to overcome low aqueous solubility.

Surface-conjugated nanoparticles on CAR T cells block adenosine-mediated immunosuppression, restoring effector function in solid tumors.

Cysteine-enriched nutritional composition increases food intake to counteract ageing-associated anorexia and malnutrition.

LOU064 selectively inhibits Bruton tyrosine kinase, resolving adverse effects from non-specific inhibitors while treating hidradenitis suppurativa.

AHR ligands linked to biocompatible nanoparticles modulate Foxp3 gene expression to enhance regulatory T cell populations.

Effervescent N-acetylcysteine tablets use sucralose to mask unpleasant degradation tastes while maintaining low total weight.

Compounds block VEGF and PDGF receptors simultaneously, addressing insufficient therapeutic effects from single pathway targeting.

Circulating extracellular vesicle biomarkers replace invasive lung biopsies to detect preclinical pulmonary fibrosis early.

Selective BTK inhibitor rilzabrutinib targets B cell activation pathways to treat immune thrombocytopenia.

Boronic acid compounds inhibit 3CLpro viral replication through reversible non-covalent binding mechanisms.

Segmented nucleic acid constructs encode distinct epitopes routed to MHC class I and II pathways for optimized immune presentation.

Alkaline birch ash extract breaks down plant cell membranes to release bioactive compounds, resolving low recovery efficiency of conventional water solvents.

A fospropofol dosage form co-administered with a pharmaceutically acceptable acid to enhance oral bioavailability.

Isotopic substitution of hydrogen with deuterium in 4-butyl-α-agarofuran improves oral bioavailability and reduces liver cytochrome P450 enzyme induction.

Substituted piperazinyl derivatives overcome cancer cell resistance mechanisms by altering pharmacokinetic properties to maintain treatment effectiveness.

NXTAR-derived oligonucleotides bind to androgen receptor mRNA sequences to inhibit protein translation.

Carbonylamino pyrrolopyrazole compounds inhibit PAK4 kinase activity, resolving the trade-off between targeting precision and synthesis complexity.